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Abstract 22 
The pancreatic islet is a complex mini organ composed of a variety of endocrine cells and 23 
their support cells that work in concert to tightly control blood glucose homeostasis. Changes in 24 
glucose concentration are commonly regarded as the chief signal controlling insulin-secreting 25 
beta cells, glucagon-secreting alpha cells, and somatostatin-secreting delta cells. However, each 26 
of these cell types is highly responsive to a multitude of endocrine, paracrine, nutritional, and 27 
neural inputs, which collectively shape the final endocrine output of the islet. Here we review the 28 
principal inputs for each islet cell type and the physiological circumstances in which these 29 
signals arise through the prism of the insights generated by transcriptomes of each of the major 30 
endocrine cell types. A comprehensive integration of the factors that influence blood glucose 31 
homeostasis is essential if we are to succeed in improving therapeutic strategies to better manage 32 
diabetes. 33 
 34 
35 
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Introduction  36 
Over the past four decades, the number of adults with diabetes has nearly quadrupled 37 
with over 420 million individuals estimated to be affected by the disease worldwide1. As these 38 
numbers are expected to continue to rise, it is evident that improved therapeutic strategies to 39 
manage diabetes are necessary. Diabetes is a disease of chronically high blood glucose stemming 40 
principally from insulin impairment. However, defects in glucagon secretion – inappropriate 41 
hyperglucagonaemia as well as impaired counterregulation – are also inextricably intertwined 42 
with the etiology of diabetes2. This places the source of insulin and glucagon – the pancreatic 43 
islets – in the crosshairs of researchers’ attempts to understand and ameliorate the disease. A 44 
better appreciation for the mechanisms controlling islet hormone secretion is imperative to 45 
developing better strategies for dealing with diabetes. 46 
The pancreatic islets are a heterogeneous mixture of endocrine cells and non-endocrine 47 
support cells that maintain homeostatic blood glucose levels via balanced hormone secretion. 48 
The beta cells make up (50-75%) of the islet cell mass in humans, and 60-80% in mice [Figure 49 
1]3-5, and are the sole source of insulin in the body6. Insulin release, triggered by increased blood 50 
glucose7,8, lowers glycaemia through the net effect of decreased glycogenolysis and 51 
gluconeogenesis at the liver and skeletal muscle and increased uptake of glucose in the liver, 52 
skeletal muscle, and adipose tissue9,10 [Figure 2]. Insulin further stimulates nutrient uptake and 53 
triglyceride (TG) synthesis in adipocytes. Collectively these insulin actions restore 54 
normoglycaemia following a meal. Alpha cells are the second most abundant islet cell type, 55 
accounting for approximately 15-20% and of the endocrine cells in mice, and 25-35% in humans 56 
[Figure 1] 3-5. Alpha cells secrete glucagon as a counterregulatory signal in response to 57 
hypoglycaemia, and is additionally potentiated (amplified) by adrenergic stimulation and 58 
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circulating amino acids. Glucagon increases hepatic glucose production primarily via increased 59 
glycogenolysis and gluconeogenesis [Figure 2]11. Delta cells make up 5-10% of the islet3 and 60 
release somatostatin dose-dependently in response to high glucose12,13. While insulin and 61 
glucagon are true hormones that are released into the circulation to elicit effects on target cells 62 
distant from site of release, somatostatin instead provides local inhibitory control over alpha and 63 
beta cells14-16. Nevertheless, this local regulation helps determine the homeostatic set point for 64 
plasma glucose17. 65 
However, beyond glucose, multiple levels of paracrine, endocrine, neuronal, and 66 
nutritional inputs collectively determine islet cell activity. In this review, we focus on emerging 67 
themes with regards to control of islet endocrine function. Part of this discussion will incorporate 68 
insights gained from islet cell transcriptomes that have provided a wealth of information on the 69 
inputs that do, and do not, impinge on the islet cell types they were long thought to act upon. It is 70 
not our intent to cover all possible inputs that have been attributed to islets over many years. We 71 
refer the interested reader to comprehensive descriptions of important topics such as species 72 
differences10,18, islet innervation19, and islet cell receptors20-22 that have been published 73 
elsewhere. Additionally, non-endocrine islet cells such as macrophages, endothelial, and stellate 74 
cells make important contributions to the islet as a functional unit [Box 1] that we will not 75 
address in detail.  76 
 77 
Goal of Review 78 
Our goal with this review is to focus on areas where recent insights challenge us to 79 
reconsider traditional views of the physiological mechanisms that control islet hormone release, 80 
and we discuss specific differences between rodent and human islets where appropriate. One 81 
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major theme is the renewed appreciation for amino acids as significant contributors to nutrient-82 
stimulated alpha cell secretion. With regards to intra-islet crosstalk, increased evidence of alpha 83 
cell-mediated beta cell potentiation now compels us to reconsider the view of glucagon as a 84 
predominantly counterregulatory hormone in favor of a model where glucagon also makes 85 
significant physiological contributions to glucose-stimulated insulin secretion. Additionally, 86 
delta cells have emerged as physiologically important modulators of insulin and glucagon 87 
secretion. Finally, we discuss how the inputs that coordinate insulin and glucagon release from 88 
healthy islets are affected by diabetes and how a better understanding of the physiological inputs 89 
into the healthy islets may be leveraged towards improved management in disease.  90 
 91 
The complexities of studying islet endocrine cells 92 
Multiple layers of nutrient, paracrine, endocrine, and neuronal signals modulate the islet 93 
cell hormone secretion that is triggered by glucose levels. The mammalian islet is highly 94 
vascularised23, allowing for both rapid sensing of changes in nutritional status or circulating 95 
hormones, and for swift delivery of insulin or glucagon to peripheral tissues. Islets are also 96 
tightly innervated by autonomic neurons23 which supports sympathetic and parasympathetic 97 
modulation of insulin, glucagon, and somatostatin release [Figure 2]. Briefly, the net effect of 98 
sympathetic stimulation is an increase in glucagon release and a decrease in insulin and 99 
somatostatin release19,24. Net parasympathetic signaling activates both insulin and glucagon 100 
secretion while decreasing somatostatin. Interestingly, islet cells also synthesise a number of 101 
classic neurotransmitters such as GABA, acetylcholine, and serotonin for intra-islet signaling 102 
independent of innervation (detailed below)25-27. And while mouse islets have historically been 103 
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suggested to be more highly innervated than human islets28, there are also reports showing 104 
prominent autonomic innervation of humans islets23. 105 
The plethora of input signals that target the islet as a functional unit has made it a 106 
challenge to distinguish direct versus indirect mechanisms that modulate alpha and beta cell 107 
activity. In recent years, islet cell type-specific reporter mice29 and antibodies30, supported by 108 
advances in RNA-Seq approaches, have made it possible to disentangle how multiple layers of 109 
external and intra-islet signals affect each individual cell type. These efforts have generated 110 
comprehensive, high-quality bulk and single cell transcriptomes of mouse and human islet 111 
cells31-34. Advances in functional imaging and electrophysiology have similarly made 112 
characterising islet responses much more cell-type specific: Genetically-encoded calcium 113 
indicators have improved upon traditional calcium dyes by enabling targeted functional imaging 114 
of populations of a single cell type33. In parallel, patch-clamp recordings aggregated across 115 
hundreds of islet cells provide us with cell type-specific electrophysiological fingerprints35. And 116 
Patch-Seq provides a unique approach to validate single cell transcriptomes with direct 117 
functional correlates acquired by patch-clamp measurements on the same single cell36,37. These 118 
technical advances now make it more feasible than ever to distinguish direct versus indirect 119 
actions on islet cells with single cell resolution.  120 
As detailed in this review, the collective inputs that influence islet secretion are 121 
sufficiently similar between mice and humans that mouse models, with their ease of 122 
experimental manipulation, offer unparalleled advantages in understanding islet biology. 123 
Nevertheless, species differences do exist. Mouse islets are organised as a core of beta cells 124 
surrounded by a mantle of alpha and delta cells [Figure 1]3. This same architecture is seen in 125 
islets from young humans, but adult human islets exhibit a variable assortment of islet 126 
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architecture from the rodent-like mantle-core organisation to a more intermingled distribution of 127 
alpha, beta, and delta cells – a setup well suited for paracrine signaling through the interstitial 128 
space10,38,39. And while many islet paracrine signals are shared between species, although some 129 
such as islet amyloidogenic polypeptide (IAPP) and peptide YY (PYY) are notably enriched in 130 
mouse over human islets22,40. Morphologically, human delta cells are relatively compact while 131 
mouse delta cells have long, neuron-like projections, which may help them overcome the 132 
distance from mantle to core when releasing somatostatin to inhibit beta cell activity15. In spite of 133 
these differences, mouse and human islets share responses to many external factors and intra-134 
islet paracrine signals that shape the final islet output. 135 
 136 
Nutrient stimulation of alpha, beta and delta cells  137 
Most textbooks offer the glucose-centric view that insulin secretion is triggered when 138 
glucose values rise over a threshold of 5 mM (7 mM in mice)41. Meanwhile, alpha cells release 139 
most glucagon under hypoglycemic conditions, and demonstrate modest glucagon secretion 140 
under hyperglycemic conditions. However, insulin and glucagon play a large role in the 141 
metabolism of not only carbohydrates, but also of lipids (free fatty acids)9,42 and proteins (amino 142 
acids)9,43 as detailed in this section. 143 
 144 
Glucose-Stimulated Insulin and Somatostatin Secretion 145 
Glucose is arguably the single most important signal that controls insulin release, 146 
although glucose fluctuations in healthy subjects are relatively modest and would not by 147 
themselves elicit robust insulin secretion. Full insulin secretion in vivo requires glucose 148 
stimulation that is potentiated by the combined actions of other nutrients, endocrine, and 149 
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paracrine factors. Glucose-stimulated insulin secretion (GSIS) is initiated when beta cells sense 150 
increases in blood glucose via glucose transporters (GLUT1 in humans and Glut2 in mice)44,45 151 
[Figure 3]. This glucose serves as a substrate for glycolysis and oxidative phosphorylation, 152 
generating ATP and leading to an accompanying drop in ADP levels. This shift in ATP/ADP 153 
ratio closes ATP-sensitive potassium channels (KATP channels), which causes membrane 154 
depolarisation. This in turn opens L-type voltage-gated Ca2+ channels (VGCCs), leading to a 155 
Ca2+ influx and calcium-induced calcium release that triggers exocytosis of insulin secretory 156 
granules18. While L-type VGCCs are responsible for the majority of Ca2+ currents in mouse beta 157 
cells, in humans P/Q-type VGCCs are about equally as involved as L-type channels41.  158 
The delta cell signal transduction for glucose-stimulated somatostatin secretion (GSSS) 159 
shares many features with beta cells15 albeit with a few distinctions. KATP channel closure and 160 
subsequent membrane depolarisation is required, but in contrast with beta cells, calcium-induced 161 
calcium release plays a larger role in GSSS than in GSIS46. Additionally, delta cells have been 162 
suggested to be electrically coupled to beta cells47. The propagation of depolarisation from 163 
glucose-activated beta cells to delta cells may help potentiate somatostatin release. However, 164 
delta cells are active at lower glucose concentrations than beta cells, possibly due to a difference 165 
in KATP activity48. Moreover, somatostatin secretion in response to hyperglycemia is 166 
synchronous with insulin secretion, albeit with a 30 second to 2 minute delay49. Such a delay is 167 
not readily reconciled with a model where delta cells operate in lock-step with beta cells 168 
mediated solely through gap junction-mediated coordination and suggests an important paracrine 169 
component to the coordination between beta and delta cells. 170 
 171 
Glucose-Mediated Glucagon Secretion 172 
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The mechanism underlying glucose-mediated alpha cell activation remains incompletely 173 
understood. Alpha cells express analogous machinery to that used for GSIS in beta cells and 174 
similarly rely on KATP channels and VGCCs for secretion, yet alpha cells are active at low as 175 
opposed to high glucose. While there is no consensus paradigm for glucagon secretion, one 176 
current model is that increasing glucose induces a KATP-driven depolarisation to inactivate 177 
voltage-gated Na+ channels50. By driving Na+ channels to a non-conducting state, alpha cells are 178 
unable to reach the membrane potential necessary for VGCC-opening and cease to secrete 179 
glucagon. Conversely, under hypoglycemic conditions, alpha cell KATP channels operate at a low 180 
level that holds alpha cells in an electrically active state and causes small depolarisations that 181 
open P/Q-type VGCCs. While this model of alpha cell activation helps explain some of the 182 
dynamics of glucagon release, a full explanation of alpha cell activity in response to 183 
hypoglycemia likely involves a combination of alpha cell-intrinsic, paracrine, endocrine, and 184 
neural factors. Indeed, when stripped of the paracrine influence of delta cells, alpha cell glucagon 185 
release is uniformly increased across a gradient of glucose concentrations51. This suggests that 186 
paracrine factors such as somatostatin have significant influence on the glucose-responsiveness 187 
of alpha cells, which we will revisit in more detail. 188 
 189 
Amino Acids 190 
Beta cells are sensitive to circulating amino acids and insulin signaling promotes both 191 
amino acid uptake and protein synthesis in skeletal muscle9. Beta cells express high levels of 192 
cationic amino acid transporters (CATs) and sodium-coupled neutral amino acid transporters 193 
(SNATs) [Figure 3c]32,33. The mechanisms by which amino acids stimulate insulin secretion 194 
vary18. Many amino acids including arginine, lysine, leucine, and glutamine depolarise beta cells 195 
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upon import, either directly if they carry a positive charge52, or due to sodium co-transport53. The 196 
ensuing depolarisation triggers Ca2+ influx to stimulate insulin release54. In parallel, amino acids 197 
such as alanine, glutamic acid and glutamine can fuel components of mitochondrial metabolism, 198 
thus increasing the ATP/ADP ratio55. Other amino acids such as glycine potentiate insulin 199 
secretion via its ionotropic glycine receptor (GlyR) on the beta cell surface56 [Figure 3c]. 200 
Furthermore, paracrine interactions contribute to the effects of amino acids on insulin.  201 
Alpha cells are highly sensitive to increases in amino acids, and are stimulated by 17 of 202 
the 20 natural amino acids57. This largely explains the post-prandial spike in glucagon in 203 
response to a normal mixed meal58. It is vital that glucagon is released along with insulin in 204 
response to amino acids as the two hormones will synergistically increase amino acid uptake in 205 
response to protein ingestion while effectively countering each other’s actions on carbohydrates. 206 
Glucagon signaling in the liver increases hepatic utilisation of amino acid substrates in 207 
gluconeogenesis43, leading to a decrease in circulating amino acids. This important safety 208 
mechanism ensures normoglycemia during protein-rich, carbohydrate-low diets58. The liver-209 
alpha cell axis that connects alpha cells, amino acids, and the liver is one of the primary 210 
mediators of amino acid homeostasis, highlighting the important role of glucagon in the post-211 
prandial state.  212 
The exact mechanism by which most amino acids directly stimulate glucagon secretion is 213 
less characterised than in beta cells, but likely involves similar mechanisms. Arginine is a potent 214 
stimulator of glucagon secretion that directly depolarises the alpha cell upon cellular transport 215 
into the cell59. Other amino acids induce glucagon secretion following import via abundantly 216 
expressed CATs and SNATs [Figure 3c] followed by use as metabolic substrate32,33. Glycine, 217 
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signaling through ionotropic GlyR, can increase intracellular Ca2+ and stimulate exocytosis in 218 
alpha cells independent of amino acid transporters60. 219 
Much like peripheral insulin resistance causes hyperglycemia, which in turn contributes 220 
to beta cell hyperplasia (at least in mice), a similar relationship is emerging between hepatic 221 
glucagon signaling, amino acid levels and alpha cell mass. Chronically elevated amino acids can 222 
influence the total capacity for glucagon secretion by stimulating alpha cell proliferation through 223 
mTOR signaling61. Indeed, in glucagon receptor knockout mice or mice treated with glucagon 224 
receptor antagonists, interrupted hepatic glucagon signaling causes a marked accumulation of 225 
serum amino acids that triggers a remarkable alpha cell hyperplasia62. This expansion is largely 226 
driven by glutamine and alanine, which activate mTor signaling in alpha cells through SNAT5 227 
(Slc38a5) in mice and an as of yet unknown amino acid transporter in humans61,63. These drastic 228 
alpha cell phenotypes are supported by clinical evidence. Hyperaminoacidemia is accompanied 229 
by hyperglucagonemia in patients with impaired liver function64,65. Interestingly, the liver-alpha 230 
cell axis appears to function independently of glucose levels as a comparison between diabetic 231 
and non-diabetic patients with non-alcoholic fatty liver disease revealed no correlation of glucose 232 
levels to elevated amino acids and glucagon64,65.  233 
 234 
Lipids 235 
Insulin regulates lipid metabolism by promoting glucose uptake for conversion into 236 
triglycerides, while simultaneously inhibiting lipolysis9. The net effect of this is to promote 237 
glucose storage as triglycerides in adipocytes. Beta cell sensitivity to circulating fatty acids in 238 
addition to glucose is therefore important to nutrient balance. Beta cell secretion is stimulated by 239 
fatty acids of varying chain length and saturation level66,67. These effects are mediated by fatty 240 
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acid receptor signaling as well as by signaling downstream of intracellular fatty acid 241 
metabolism68. The primary receptor for circulating fatty acids expressed by mammalian beta 242 
cells is free fatty acid receptor 1 (FFAR1/Ffar1; a.k.a. GPR40), a Gαq-coupled G protein-coupled 243 
receptor (GPCR)33,69 [Figure 3b]. FFAR1 supports medium- to long-chain saturated fatty acid as 244 
well as unsaturated fatty acid signaling. Most studies on FFAR1 have focused on the actions of 245 
palmitate – one of the most abundant circulating saturated fatty acids69,70. The Gαq signaling 246 
cascade activates phospholipase C (PLC) and induces 1,4,5 inositol-triphosphate (IP3) formation. 247 
This mobilises Ca2+ from the ER, which in beta cells triggers insulin secretion71. Acute 248 
Ffar1/FFAR1 activation on the minute-to-hour timescale in mouse72 and human73 islets increases 249 
insulin secretion at high glucose levels, and the strength of insulin secretion increases with the 250 
length of the FFA chain74. Conversely, chronic (multi-day) palmitate exposure induces 251 
dissociation between insulin granules and VGCCs that drive secretion, which results in insulin 252 
secretion being decreased by more than 50%73,75. Separate of IP3-mediated activation, fatty acids 253 
that diffuse into beta cells can be converted into triglycerides and diacylglycerol that feed into 254 
GSIS amplification pathways or directly induce insulin exocytosis68, independent of fatty acid 255 
receptors. Indeed, palmitate increases the calcium currents and increases the readily-releasable 256 
pool of insulin-containing granules76.  257 
The degree to which free fatty acids directly affect glucagon secretion has been debated 258 
for decades. Early studies suggested that alpha cells were actually inhibited by free fatty acids77, 259 
but there is growing evidence of an activating role78,79. Similar to beta cells, human alpha cells 260 
express the activating receptor, FFAR132. In both mice and humans, glucagon release is directly 261 
stimulated by long-chain fatty acids via the resulting downstream increase in cytosolic Ca2+78,79. 262 
Glucagon’s role is primarily to modulate hepatic lipid catabolism. Glucagon signaling at the liver 263 
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increases fatty acid beta oxidation42 and decreases lipoprotein synthesis and secretion80,81. At the 264 
adipose tissue glucagon stimulates lipolysis, although this is balanced by simultaneous lipolysis 265 
inhibition by insulin9. Alpha cell sensitivity to circulating free fatty acids is thus an important 266 
contributor to whole body lipid metabolism.  267 
In both mice and humans, delta cells preferentially express free fatty acid receptor 4 268 
(FFAR4/Ffar4; a.k.a. GPR120) [Figure 3b]33, which is a Gαi-coupled GPCR. Gαi signaling 269 
inhibits adenylyl cyclase, which catalyses the formation of cyclic AMP (cAMP). As cAMP 270 
potentiates hormone secretion in islet cells, activation of Ffar4 in delta cells inhibits somatostatin 271 
secretion by 50%79,82. Together, these fatty acid receptor profiles illustrate a system where, in the 272 
presence of high circulating free fatty acids, the combined activation of insulin and glucagon is 273 
augmented by disabling the inhibitory actions of delta cells to handle this increased lipid load. 274 
 275 
Paracrine Signaling in the Islet 276 
Although nutrients are significant inputs to stimulate insulin and glucagon release, the 277 
islet itself is a rich source of signals that engage in intra-islet crosstalk. Paracrine signaling 278 
provides an additional layer of control over islet endocrine output that is essential for 279 
maintaining establishing and maintaining the homeostatic glucose setpoint. In particular, we will 280 
focus on recent developments in the paracrine actions of alpha cells on beta cells – and vice 281 
versa – as well as the overarching role of intra-islet delta cell signaling. 282 
 283 
Alpha Cell-Mediated Beta Cell Activation 284 
It would seem intuitive for beta and alpha cell activity to be mutually suppressive given 285 
that insulin and glucagon are functional antagonists, at least when it comes to maintaining 286 
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euglycemia. Yet, while beta cell activity suppresses alpha cells (mediated at least in part via delta 287 
cells as will be discussed later), glucagon from alpha cells has long been known to stimulate 288 
insulin secretion83. While an arrangement where alpha cells stimulate beta cells, beta cells inhibit 289 
alpha cells, but stimulate delta cells, and delta cells inhibit both may appear counterintuitive 290 
(Figure 4a), modeling studies validate that this is the most stable way to organise a 3-node 291 
interaction84. It is increasingly apparent that beta cells require alpha cell inputs for full insulin 292 
secretion and establishing normoglycemia85. This realisation warrants a paradigm shift in our 293 
thinking of alpha cells as not only mediators of counterregulatory hepatic glucose production, but 294 
also as an important local source beta cell potentiation. The following section highlights local 295 
alpha cell secretions that potentiate beta cell activation, namely glucagon as well as acetylcholine 296 
and corticotropin-releasing hormone. 297 
 298 
The Traditional Incretin Effect  299 
Incretins are classically defined as enteroendocrine hormones that potentiate GSIS. The 300 
two main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 301 
peptide (GIP). GLP-1 is produced by L-cells in the intestinal ileum and derives from the same 302 
precursor protein as the glucagon that is released by pancreatic alpha cells. In L-cells, 303 
proglucagon is cleaved by proprotein convertase 1/3 (PCSK1/3) to produce GLP-1, while alpha 304 
cells express PCSK2 that produces glucagon instead. GIP is released from K cells in the 305 
duodenum and jejunum86.  306 
Together, incretins are believed to be responsible for as much as half of the insulin 307 
response to a carbohydrate meal87,88. Beta cells express relatively high levels of the GLP-1 308 
receptor (GLP1R/Glp1r), while the GIP receptor (GIPR/Gipr) is more broadly expressed in 309 
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multiple islet cells [Figure 3b]. Both receptors are Gαs-coupled GPCRs that potentiate insulin 310 
secretion primarily through adenylyl cyclase activation and the resulting cAMP-mediated 311 
signaling cascade86,89. In concert with the cAMP pathway, activation of the PLC/protein kinase C 312 
(PKC) may contribute to beta cell stimulation by incretins90. This potentiation of GSIS is known 313 
as the incretin effect, whereby oral glucose consumption results in a markedly higher insulin 314 
response compared to intravenous administration in which glucose bypasses the GI tract. 315 
Incretins also stimulate an expansion of beta cell mass via proliferation, which further augments 316 
total insulin secretory capacity91. However, the incretin effect is observed during the cephalic 317 
phase of a meal, before nutrients enter the gastro-intestinal tract. This constitutes a disconnect 318 
with regards to the source of the GLP-1 that potentiates GSIS long before food reaches the ileum 319 
where most L cells are located. A resolution of this conundrum may necessitate a re-evaluation 320 
of the physiological role of glucagon and incretin receptors and how they interact to potentiate 321 
GSIS. 322 
 323 
Intra-Islet Glucagon Signaling  324 
Glucagon has been known to be able to potentiate GSIS in a manner reminiscent of the 325 
incretin effect since the 1960s83, but the importance of this local action of glucagon for islet 326 
function is only now coming into full view. Mammalian beta cells express relatively high levels 327 
of glucagon receptor (GCGR/Gcgr) [Figure 34], as well as GLP1R and GIPR. All these receptors 328 
belong to the same family of GPCRs that share similar cAMP-mediated downstream signaling 329 
mechanisms. Glucagon and GLP-1 are both derived from proglucagon, and signal via receptors 330 
that share 47% sequence homology92, which points to the potential for cross-reactivity between 331 
glucagon and GLP-1 and their receptors in the islet. 332 
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Indeed, multiple groups have now independently demonstrated that proglucagon-derived 333 
peptides produced by alpha cells activate beta cells via either GCGR or GLP1R and that these 334 
actions are required for normal GSIS in humans and mice93-98. The majority of circulating GLP-1 335 
is derived from the GI tract, and knocking out gut-derived GLP-1 is impairs oral glucose 336 
tolerance99. However, islet-specific GLP-1 signaling, without any contribution from the gut, is 337 
shown to be necessary for normal glucose handling94. Separate studies have demonstrated that 338 
simultaneously knocking down or blocking both GLP1R and GIPR in beta cells severely reduces 339 
glucose-stimulated insulin secretion and glucose tolerance93,95. Glucagon is the predominant 340 
alpha cell ligand in mouse islets that engages both GCGR and GLP1R on beta cells to mediate 341 
most of this intra-islet signaling93,95. While alpha cells can produce GLP-1 under certain 342 
circumstances100, wild type mouse islets under normal circumstances secrete relatively little 343 
GLP-195.  344 
The activation of GLP1R and other Gαs-coupled GPCRs such as GCGR and CRHR1 (see 345 
below) on beta cells in response to locally released, alpha cell-derived hormones represents a 346 
paradigm shift in our understanding of how insulin release can be potentiated. For instance, 347 
amino acids such as arginine and glutamine may elicit insulin secretion at least in part by 348 
stimulating glucagon release, which then indirectly promotes insulin release in a paracrine 349 
fashion, and not by direct stimulation of beta cells as was previously thought93. Such a scenario 350 
likely requires beta cell triggering by glucose, which is going to be present along with amino 351 
acids in most mixed-meal settings. A number of groups are pursuing GLP1R/GCGR dual 352 
agonists that may prove to be a superior method for amplifying insulin in treating type 2 diabetes 353 
given these mechanistic discoveries101,102. Together, these latest series of observations suggest 354 
that we need to reconsider our definition of GSIS: instead of reflecting the direct stimulatory 355 
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effect of glucose on beta cells, GSIS from intact islets reflects the combined effects of glucose 356 
stimulation plus paracrine amplification via locally released glucagon and other alpha cell-357 
derived products [Figure 4a]. These observations also reconcile the traditional view of glucagon 358 
as a counterregulatory hormone with the long-known ability of glucagon to potentiate GSIS83. 359 
 360 
Corticotropin-Releasing Hormone 361 
Corticotropin-releasing hormone (CRH/Crh), originally discovered as the principal 362 
hypothalamic factor to initiate ACTH release from the anterior pituitary, is also expressed 363 
abundantly in human and rat alpha cells32,103. Interestingly, mouse alpha cells do not express Crh 364 
peptide or mRNA32, although beta cells of mice, rats, and human all express corticotropin 365 
releasing hormone receptor 1 (CRHR1/Crhr1) [Figure 3b]104. CRHR1 is a Gαs-coupled GPCR 366 
that is related to the incretin receptors. Treating beta cells with CRH predictably induces a 367 
cAMP-mediated Ca2+ influx105, potentiates GSIS, protects against cytokine-induced beta cell 368 
apoptosis, promotes beta cell proliferation, and stimulates the expression of an immediate early 369 
gene signature106. While the physiological contribution of CRH derived from alpha cells remains 370 
untested, it is another alpha cell-derived peptide that is poised to potentiate GSIS. 371 
 372 
Acetylcholine  373 
In mice, acetylcholine originates from parasympathetic neurons innervating the islet19 374 
[Figure 2]. In human islets, acetylcholine is released locally from alpha cells26,107 [Figure 4a]. 375 
Irrespective of whether acetylcholine is of neural or paracrine origins, acetylcholine potentiates 376 
insulin secretion from mouse and human islets via the Gαq-coupled muscarinic 3 cholinergic 377 
receptor (CHRM3/Chrm3) [Figure 3b]26,107-109. Acetylcholine’s effect on alpha cells is species-378 
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dependent. Human alpha cells do not respond to exogenous cholinergic as they synthesize their 379 
own acetylcholine107. Meanwhile, mouse alpha cells can be activated by cholinergic 380 
stimulation110, although the underlying mechanism may be indirect as cholinergic cholinergic 381 
receptors are enriched in beta and delta cells (Figure 3). In contrast to its stimulation of beta 382 
cells, acetylcholine inhibits glucose-induced somatostatin secretion from delta cells. 383 
Parasympathetic tone is known to inhibit somatostatin release24, and in mouse islets, cholinergic-384 
mediated inhibition is prevented by pertussis toxin, suggesting the involvement of Gαi-mediated 385 
signaling111. This is in line with the selective expression by mammalian delta cells of the Gαi-386 
coupled muscarinic 4 cholinergic receptor (CHRM4/Chrm4) [Figure 3b]. These observations 387 
support a model where cholinergic signals (derived from parasympathetic innervations or from 388 
alpha cells in humans islets) amplifies insulin release directly and indirectly by inhibiting delta 389 
cells [Figure 2, 4a]. It should be noted that, in direct contrast with acetylcholine-mediated delta 390 
cell inhibition, other groups have reported IP3-mediated stimulatory effects of cholinergic 391 
agonists on somatostatin secretion from mouse46 and human107 islets. Another way to use 392 
transcriptomes for decrypting signaling targets beyond just receptor profiles is to interrogate 393 
synthesis and degradation pathways for signaling molecules. Delta cells fit the profile of a target 394 
of cholinergic signaling given their receptor expression and the preferential expression of the 395 
enzyme acetylcholinesterase33, which, in neurons, breaks down acetylcholine at the postsynaptic 396 
membrane112. The coordinated actions of acetylcholine on beta and delta cells during 397 
normoglycemia may therefore contribute to the maintenance of basal insulin release between 398 
meals. 399 
 400 
Beta Cell-Mediated Alpha Cell Inhibition  401 
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There is general agreement in the field that beta cell-derived products contribute to alpha 402 
cell silencing at high glucose. Insulin, serotonin, GABA, and zinc are some of the beta cell 403 
factors proposed to directly inhibit alpha cells. Beta cells also secrete the peptide hormone 404 
urocortin 3 at high glucose, which potentiates delta cell glucose-stimulated somatostatin 405 
secretion. Given that somatostatin is a powerful inhibitor of glucagon secretion, urocortin 3-406 
mediated stimulation of somatostatin release represents an indirect mechanism by which beta 407 
cells may suppress glucagon release during high glucose. Many papers over the years have 408 
favoured one signal over the other for reasons we will review here. It is plausible that there is 409 
redundancy or additivity among these beta cell-derived signals in their ability to suppress alpha 410 
cells, or that they play similar roles in distinct physiological settings. 411 
 412 
Insulin 413 
While it is difficult to disentangle which of several beta cell-derived paracrine signal may 414 
be principally responsible for suppressing alpha cells at high glucose, multiple groups have 415 
reported decrements in glucagon upon direct insulin administration113-116. Human and mouse 416 
alpha cells express the insulin receptor (INSR/Insr)32,33, which can maintain KATP channels in the 417 
open configuration via PI3K/AKT signaling when activated. Open KATP channels drive alpha 418 
cells to a hyperpolarised state that prevents glucagon granule exocytosis [Figure 4a]115. Mice 419 
with an alpha cell-specific deletion of Insr exhibit increased glucagon secretion, and as a result 420 
develop hyperglycemia and glucose intolerance114. However, this effect is milder than expected 421 
given the amount of insulin present locally within the islet and is by itself insufficient to explain 422 
beta cell-mediated alpha cell inhibition. Indeed, knocking out the insulin receptor in delta cells 423 
results in lower somatostatin release and alpha cell insensitivity to insulin indicating 1) insulin 424 
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also has a paracrine effect potentiating delta cells, and 2) that the inhibition of alpha cells by 425 
insulin is mediated at least in part indirectly via somatostatin117.  426 
 427 
Serotonin 428 
Serotonin is a neurotransmitter derived from tryptophan that regulates mood and anxiety 429 
in the brain. Beta cells express all of the components for serotonin production – tryptophan 430 
hydroxylase (TPH1,TPH2) and DOPA decarboxylase (DDC) – and vesicular loading – Vesicular 431 
monoamine transporter 1 and 2 (SLC18A1 and SLC18A2)118,119. Beta cell serotonin synthesis is 432 
more pronounced in females and is further enhanced during pregnancy and old age119,120. In 433 
humans, serotonin from beta cells is released at high glucose and acts in a paracrine manner, 434 
inhibiting neighbouring alpha cells via the Gαi-coupled serotonin receptor 1F (HTR1F)27,32. Early 435 
clinical studies where healthy human volunteers were administered serotonin antagonists 436 
reported increased glucagon secretion121.  437 
 438 
GABA 439 
GABA is the classic inhibitory neurotransmitter of the CNS, and while it plays a role in 440 
islet signaling, neurogenic GABA’s contribution appears to be minor. Beta cells are able to 441 
synthesise GABA at some of the highest concentrations outside the CNS, with islet tissue 442 
content measurements in the millimolar range; comparable to local insulin concentrations at 443 
basal glucose25,122. Glutamic acid decarboxylase 1 (GAD1), the enzyme that synthesises GABA, 444 
is highly enriched in beta cells and is a major Type 1 Diabetes autoantigen32,33. In rodents, 445 
GABA inhibits alpha cells through ionotropic GABA A receptors123-125 [Figure 3b], although 446 
metabotropic GABA B1 receptor expression is also detectable. GABA from beta cells has been 447 
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proposed to be the reason alpha cells are silenced at high glucose concentrations124, but GABA 448 
treatment by itself does not fully suppress rodent glucagon secretion126. The fact that GABA A 449 
receptors are difficult to detect on human alpha cells and that the application of GABA elicits 450 
little electrophysiological response127 argue against GABA as a significant contributor to alpha 451 
cell inhibition during hyperglycemia [Figure 4a]. 452 
 453 
Zinc  454 
Insulin secretory granules in the beta cells are highly enriched for zinc ions (Zn2+) to 455 
facilitate the formation of the insulin crystal128. Zn2+ co-released with insulin has therefore been 456 
considered as another beta cell product poised to inhibit alpha cells129,130. Zn2+ is taken up by the 457 
zinc transporter Znt8 (SLC30A8), which is abundantly expressed by both alpha and beta 458 
cells32,33,131 [Figure 3c]. However, whole body, beta-specific, and alpha-specific Znt8 deletion 459 
does not affect glucagon secretion131,132, indicating that Zn2+ is unlikely to contribute to beta cell-460 
dependent inhibition of glucagon under high glucose. 461 
 462 
Delta Cell-Mediated Islet Hormone Coordination 463 
 The delta cells have emerged as important inhibitory modulators of alpha and beta cell 464 
activity and physiological metabolism. Somatostatin is an important local factor controlling and 465 
coordinating the amount and timing of insulin and glucagon release from the islet, which 466 
ultimately contributes to setting homeostatic blood glucose levels.  467 
 468 
Somatostatin  469 
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Somatostatin has important inhibitory functions in the GI tract as well as the anterior 470 
pituitary gland. Since delta cell-derived somatostatin accounts for only 5-10% of systemic 471 
circulating somatostatin content, its predominant function is likely as a paracrine regulator15,16. 472 
Delta cells are active throughout the majority of the physiological range of glucose with 473 
secretion starting as low as 3 mM glucose and increasing in a linear, dose-dependent manner 474 
towards 20 mM12,15,133. This large range of activity may have direct implications in the inhibition 475 
of both alpha and beta cells. 476 
There are five somatostatin receptor (SSTR/Sstr) isoforms – all of which are Gαi-coupled 477 
GCPRs134. The most abundant form expressed by mouse beta cells is Sstr3 [Figure 3b]31,33,135. 478 
The predominant SSTR(s) on human beta cells remains unclear as some combination of SSTR1, 479 
SSTR2, SSTR3 and SSTR5 are expressed32 and impact insulin secretion to some degree136,137. In 480 
addition to preventing hormone secretion by decreasing adenylyl cyclase activity, somatostatin 481 
receptor signaling simultaneously activates G protein-gated inwardly-rectifying K+ (GIRK) 482 
channels that can counteract glucose-mediated membrane depolarisation137 and inactivates 483 
VGCCs that are critical to insulin release138. Somatostatin released during high glucose provides 484 
inhibitory feedback that – under physiological conditions – does not fully shut down beta cells, 485 
but rather provides tonic inhibition. We have proposed that this arrangement is likely 486 
instrumental in preventing insulin release in excess of what is required to restore normoglycemia, 487 
and in doing so prevents insulin-induced hypoglycemia17. The local release of somatostatin 488 
during high blood glucose thus provides an additional layer of control to establish and stabilise 489 
blood glucose around its homeostatic setpoint. 490 
Alpha cell activity is controlled by delta cells as the majority of the glucagonostatic effect 491 
of high glucose requires the paracrine actions of somatostatin. Somatostatin inhibits alpha cells 492 
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primarily via SSTR2 in mouse and human islets with additional contribution of SSTR1 in 493 
humans31,33,137,139. While somatostatin-independent factors such as glucose contribute to 494 
inhibition, alpha cells are under constant tonic inhibition from delta cells. In mice, glucagon 495 
output increases across the full range of physiological blood glucose levels when either 496 
somatostatin is knocked out140 or when islets are treated with Sstr2 antagonists or inhibitors of 497 
downstream somatostatin signaling12,51,141. 498 
Based on our understanding of the inhibition provided by delta cells, it is clear that 499 
somatostatin as a paracrine regulator ultimately dictates the total alpha and beta cell output. 500 
However, delta cell activity itself is dependent on paracrine inputs as well, chief among these the 501 
beta cell hormone urocortin 3.  502 
 503 
Urocortin 3 504 
The peptide urocortin 3 (UCN3/Ucn3) is the third most abundant hormone produced by 505 
beta cells, and is a member of the same peptide hormone family as CRH14. Urocortin 3 is 506 
packaged in the same secretory granules as insulin and co-released with insulin during GSIS. 507 
Delta cell GSSS is potentiated by urocortin 3 via the Gαs-coupled GPCR, corticotropin releasing 508 
hormone receptor 2 (CRHR2/Crhr2)14, which is selectively expressed by delta cells [Figure 3b]. 509 
Beta cell activation is required for full delta cell activity at high glucose as demonstrated by 510 
impaired somatostatin release in urocortin 3 knockout mice and islets treated with a Crhr2 511 
antagonist14. Additionally, these same conditions – urocortin 3 knockout and Crhr2 antagonism – 512 
both demonstrate markedly increased GSIS, demonstrating that urocortin 3 attenuates insulin 513 
release by potentiating GSSS from delta cells in a classic negative feedback loop.  514 
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The physiological contribution of urocortin 3 to glucose homeostasis is best illustrated by 515 
the timing of its expression during development. Ucn3 is one of the last beta cell genes that is 516 
turned on during beta cell maturation; full expression does not occur until around day 14 517 
postpartum in 142 and at the end of the first trimester in human pancreas development143. The 518 
onset of urocortin 3 expression coincides with a general increase in plasma glucose levels that is 519 
correlated with a drop in circulating insulin levels144. Premature induction of urocortin 3 520 
specifically in beta cells of transgenic mice from embryonic day 10.5 onwards results in 521 
prematurely elevated blood glucose relative to control littermates14 demonstrating causality 522 
between the onset of urocortin 3 and the rise in blood glucose. Urocortin 3 thus establishes the 523 
homeostatic glucose setpoint by activating somatostatin-mediated feedback inhibition of insulin 524 
[Figure 4c].  525 
 526 
Islet signaling changes in diabetes 527 
The balance between insulin and glucagon release that is so effectively maintained by the 528 
integration of a multitude of signals that converge on healthy islets is severely disrupted in 529 
diabetes. Autoimmune attack in type 1 diabetes, or peripheral insulin resistance in type 2 530 
diabetes, ultimately leads to beta dysfunction and death6. Alpha cells in type 1 diabetes exhibit 531 
an impaired counterregulatory response to hypoglycemia145, and conversely in type 2 diabetes 532 
they aggravate hyperglycemia by inappropriate post-prandial glucagon secretion [Figure 4d]146.  533 
There is evidence that these many clinical manifestations are tied to a breakdown of the 534 
paracrine crosstalk that so tightly regulates islet function in healthy islets. The impaired alpha 535 
cell counterregulatory response has been attributed to autonomic failure, where adrenergic 536 
stimulation that assists in potentiating hypoglycemic glucagon secretion is lost147,148. A paracrine 537 
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explanation (that need not be mutually-exclusive) is that somatostatin is elevated in response to 538 
hypoglycemia in STZ-induced diabetic rats149, likely contributing to impaired counterregulatory 539 
glucagon release. Indeed, blockade of the Sstr2 that is selectively expressed by alpha cells 540 
suffices to restore counterregulation in rats150. 541 
In another example where paracrine crosstalk breaks down in diabetes, impaired 542 
urocortin 3 signaling likely contributes to dysregulated insulin, somatostatin, secretion in 543 
diabetes. In Type 1 Diabetes, the majority of beta cells are destroyed and no longer can serve as a 544 
source of local urocortin 3 [Figure 4b]. Pre-diabetic (type 2) human, NHP, and mouse beta cells 545 
selectively down regulate urocortin 3 expression14,151,152. The ensuing effects of the loss of 546 
urocortin 3 on GSSS in human and NHP islets have not been established, but islets from 547 
moderately diabetic leptin-deficient mice demonstrate a loss of urocortin 3 and consequently 548 
release little somatostatin at high glucose, despite the fact that delta cells remain in normal, or 549 
even increased numbers in diabetes14. Restoring urocortin 3 expression in diabetic mice 550 
exacerbates hyperglycemia, in line with the re-activation of beta cell inhibition by somatostatin 551 
and similar to the premature embryonic urocortin 3 induction14. The mechanism responsible for 552 
the loss of urocortin 3 expression that precipitates the breakdown of local crosstalk early in 553 
diabetes is not known, which illustrates that a better understanding of paracrine communication 554 
between islet cells is vital to improved therapeutic options.  555 
At the nutrient level, elevated blood glucose in diabetes provokes many functional 556 
changes in beta cells. Hyperglycemia contributes to beta cell proliferation in mice and ultimately 557 
leads to glucotoxicity and beta cell dysfunction. In the dysfunctional state, the loss of urocortin 3 558 
likely removes much of the somatostatin inhibition, as stated above14. Unrestrained from 559 
paracrine signals including somatostatin, alpha cells release glucagon that stimulates hepatic 560 
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glucose production and aggravates hyperglycemia [Figure 4d]. With hepatic insulin resistance, 561 
individuals can also develop impaired glucagon signaling, which inhibits gluconeogenesis and 562 
leads to an accumulation of circulating amino acids. This sets off a vicious cycle of 563 
hyperaminoacidemia and hyperglucagonemia, with neither signal efficiently correcting the 564 
other64. Initial insulin compensation in type 2 diabetes can lead to fatty infiltration where the islet 565 
microenvironment becomes filled with adipocytes23. While fatty acids will contribute to the 566 
compensatory increase in insulin release via potentiating secretion and increasing beta cell mass, 567 
extended exposure to fatty acids can lead to lipotoxic stress, beta cell dysfunction and decreased 568 
insulin secretion153. Without intervention, these initially compensatory mechanisms to increase 569 
insulin output cause a state of partial or complete beta cell dysfunction. 570 
 571 
The value of transcriptomics and pathways for drug discovery 572 
Transcriptomics supported by rigourous validation experiments via imaging and hormone 573 
secretion have rapidly advanced our grasp of islet function. Such increased mechanistic 574 
understanding can inform direct translational progress. RNA-Seq performed on islet cells from 575 
diabetic donors has allowed for direct comparisons between the healthy and diseased islet 34,154. 576 
Two examples of the insights generated by these islet cell transcriptomes are clarifications of the 577 
islet mechanisms of action of the hunger hormone, ghrelin33, and, separately, the receptor 578 
GPR119: 579 
 580 
The mechanism of ghrelin-mediated insulin suppression 581 
Ghrelin release occurs in the fasted state and inhibits insulin release from rodent and 582 
human pancreata155-157. For years, these insulinostatic actions had been attributed to direct 583 
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inhibition of beta cells by ghrelin155,158, even though the growth hormone secretagogue receptor 584 
(GHSR/Ghsr) that mediates ghrelin’s signal is a GPCR normally associated with an activating 585 
Gαq subunit159. As ghrelin’s inhibitory actions were sensitive to pertussis toxin, it was proposed 586 
that GHSR couples to an inhibitory Gαi subunit in beta cells160. However, islet cell 587 
transcriptomes from multiple groups resolved this conundrum by demonstrating that GHSR is 588 
selectively expressed by delta cells [Figure 3b], and the resulting Gαq-mediated somatostatin 589 
release from delta cells silences beta cells in a Gαi-mediated fashion31,33,161. Coupling 590 
transcriptomics to functional assays has expanded our ability to interrogate which islet cell type 591 
expresses the requisite receptors in order to respond to each respective signal that impinges on 592 
the islet. 593 
 594 
GPR119 stimulates insulin secretion indirectly via alpha cells 595 
GPR119 is a Gαs-coupled GPCR that binds lipids and lipid metabolites. The receptor has 596 
been a drug target of interest for diabetes since the discovery that GPR119 activation enhances 597 
both GSIS and incretin release162,163. Early GPR119 research found its expression to be largely 598 
limited to the pancreatic islets and GI tract, and inaccurately built a case for GPR119 as a beta 599 
cell-specific insulinotropic receptor. Following these observation, multiple companies generated 600 
small molecule agonists for GPR119164. The receptor proved to be highly druggable with a 601 
number of molecules eliciting improved glucose clearance, but efforts have stalled recently in the 602 
face of common challenges related to safety and efficacy. Moreover, drug developers may have 603 
been targeting the wrong cell type – comprehensive islet transcriptomes clearly demonstrate 604 
relatively selective expression of GPR119 by alpha cells [Figure 3b]33,40. This has been validated 605 
by a subsequent study demonstrating that GPR119 activation in mouse and human islets 606 
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improves glucagon release during hypoglycemia165. The improved GSIS that is observed in 607 
response to GPR119 agonism is likely due to the actions of glucagon potentiating GSIS from 608 
beta cells that we reviewed earlier. 609 
 610 
Conclusions 611 
While many aspects that contribute to the regulation of pancreatic islets in health and 612 
disease remain unresolved, a brief survey of recent trends in islet research shows that in taking a 613 
small step back to appreciate the islet beyond the beta cells and glucose, the diabetes field is 614 
taking significant strides forward towards a more comprehensive understanding. Shining a light 615 
on alpha and delta cells, the intra-islet crosstalk they engage in, and non-canonical nutrient 616 
signaling may turn out to be key in tackling diabetes. Especially in the context of drug discovery, 617 
these interactions cannot be ignored. The availability of comprehensive bulk and single cell 618 
transcriptomes for each islet cell type will continue to facilitate the delineation between direct 619 
and indirect effects of hormones, nutrients, and neurotransmitters. Similarly, much of the work 620 
done to date on stem cells for a cure for Type 1 Diabetes has focused on generating insulin-621 
secreting beta cell-like cells. However, it has become clear that beta cells require input from 622 
neighboring alpha and delta cells for mature beta cell function. Future studies should be 623 
cognizant of these interactions as Occam’s Razor (the simplest explanation is likely correct) 624 
applied to the pancreatic islet must account for the islet as an interactive unit where multiple 625 
endocrine and non-endocrine cell types coordinate the overall release of insulin and glucagon 626 
from the islet. 627 
628 
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 Figure 1. Comparative architecture of pancreatic islets of mice and humans. Pancreatic 1076 
islets of mice and humans differ in important ways, but also share many features in common. 1077 
These shared features make mouse islets useful experimental models to study many aspects of 1078 
human islet biology. The relative proportions of endocrine cell types in mouse (left) and human 1079 
islets (right) are similar with beta cells (β; green) comprising the majority of the islet cell mass 1080 
followed by alpha (α; light red) and delta cells (δ; yellow). Other islet endocrine cells such as 1081 
pancreatic polypeptide and epsilon cells (PP and ε; purple) are more sparse in number. Human 1082 
islets occur in a wide variety of sizes and conformations that range from highly structured to 1083 
more random distributions of cells. Mouse islets exhibit a more uniform architecture with alpha 1084 
and delta cells at the islet periphery surrounding a beta cell core. Islets in both species are 1085 
vascularised (dark red) and innervated (dark blue) for rapid sensing of changing energy needs, 1086 
although mouse islets are more densely innervated than humans.  1087 
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Figure 2. Inter-organ signaling from nutrient sensing to islet-mediated metabolic effects. 1088 
Nutrition-related signals from the gastrointestinal (GI) tract combine with neuronal input from 1089 
the autonomic nervous system (ANS) to direct insulin and glucagon secretion from pancreatic 1090 
islets. Changes in blood glucose levels are sensed by alpha, beta, and delta cells, which respond 1091 
by restoring blood glucose to homeostatic levels. Alpha cells release glucagon at low glucose to 1092 
increase hepatic glucose production. During hyperglycemia, beta cells lower blood glucose by 1093 
releasing insulin to increase glucose storage in the liver, skeletal muscle, and adipose tissue. 1094 
Insulin release is amplified by the incretin hormones GLP-1 and GIP from the small intestine as 1095 
well as by glucagon from neighbouring alpha cells. Delta cells secrete somatostatin across a 1096 
range of glucose levels, but most prominently in response to hyperglycemia. Amino acids and 1097 
free fatty acids (FFAs) stimulate both alpha and beta cells, and the peripheral effects of both 1098 
glucagon and insulin result in reduced circulating amino acids and FFAs. The central nervous 1099 
system (CNS) can augment islet secretion in conditions such as the “rest and digest” state where 1100 
direct insulin secretion is further facilitate by a suppression of somatostatin secretion by 1101 
acetylcholine (ACh) associated with parasympathetic innervation. Glucagon secretion is 1102 
increased during the “fight or flight” response by norepinephrine (NE) released by sympathetic 1103 
nerves.  1104 
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Figure 3. Visualisation of the abundance and selectivity of GPCR and transporter gene 1105 
expression in alpha, beta, and delta cells . We used the natural log of the normalised 1106 
expression values for a gene (ln[RPKM]) to plot the relative position of that gene along three 1107 
axes representing alpha, beta, and delta cells. These expression values are derived from 1108 
transcriptomes of FACS-purified mouse alpha, beta, and delta cells described elsewhere33. a) 1109 
Each of these three individual gene expression values are converted into x and y vectors and then 1110 
consolidated into a single set of x, y coordinates that represents the overall selectivity of the 1111 
expression of that gene. The origin represents equal expression (i.e. no enrichment) in each of the 1112 
three islet cell types, whereas. placement in any direction along one of the axes reflects 1113 
enrichment in the corresponding cell type. Sphere and font sizes are proportional to abundance of 1114 
the gene based on the highest RPKM value for that gene in alpha, beta, or delta cells. b) The top 1115 
150 most abundant G protein-coupled receptors (GPCR) of the islet cells are color coded in 1116 
accordance with the predominant signaling cascade associated with each receptor. Blue genes are 1117 
Gαs-coupled, green are Gαq, red are Gαi, and yellow is ‘unknown’ or ambiguous based on 1118 
receptor classifications from IUPHAR (International Union of Basic and Clinical 1119 
Pharmacology)166. c) Non-GPCR receptors and transporters are colour-coded according to the 1120 
class of signaling molecules utilised by each receptor/transporter, following IUPHAR 1121 
classification for solute carriers.  1122 
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Figure 4. Diabetes disrupts the extensive paracrine signaling network of the islet. Alpha, 1123 
beta, and delta cells influence each other’s secretion via intra-islet crosstalk. a) Coloured text 1124 
boxes (green for activating, orange for inactivating) denote the target cell type of paracrine 1125 
signaling (underlined), the signal molecule involved (bold), and the target receptor gene 1126 
(italicised). Each box is placed in between the target cell and the source of the signal. Beta cells 1127 
initiate a negative feedback loop in high glucose whereby they release urocortin 3 to activate 1128 
delta cells. The resulting somatostatin (SST) release feeds back to mediate insulin release, 1129 
providing tonic inhibition that establishes the homeostatic glucose setpoint. Beta cells also 1130 
experience paracrine activation from alpha cells, which release glucagon, acetylcholine (ACh), 1131 
and corticotropin-releasing hormone (CRH), which all potentiate GSIS. Beta cell-derived 1132 
products such as insulin, serotonin (5-HT), and GABA – in addition to urocortin 3-induced 1133 
somatostatin release – all contribute to silence alpha cells during hyperglycemia. b) The onset of 1134 
diabetes results in a loss of multiple paracrine signals. Due to autoimmune destruction, type 1 1135 
diabetic islets effectively lose all beta cell signals. In type 2 diabetes, urocortin 3 is severely 1136 
downregulated in beta cells, blunting glucose-stimulated somatostatin secretion. c) The 1137 
physiological impact of paracrine signaling can be visualised with glucose curves for each islet 1138 
hormone. The homeostatic glucose set point is maintained by glucagon raising blood glucose 1139 
during hypoglycaemia and insulin lowering glucose during hyperglycaemia. Somatostatin 1140 
contributes as a fine-tuning mechanism via paracrine inhibition of both alpha and beta cells. d) 1141 
The absence of beta cell-derived products in diabetes results in inappropriately high glucagon 1142 
secretion during high glucose, which exacerbates hyperglycaemia. Glucagon counterregulation at 1143 
low glucose is also impaired, possibly due to aberrant somatostatin secretion, although this is not 1144 
yet fully understood. Based in part on Ref17. 1145 
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Box 1. The contributions of non-canonical endocrine cells and non-endocrine cells to 1147 
proper islet function. What follows are brief descriptions of the various other cells within the 1148 
islet and their relation to intra-islet signaling and diabetes.  1149 
PP/gamma cells  1150 
Pancreatic polypeptide (PP) cells are the fourth islet endocrine cell type, which comprise <5% of 1151 
human and <2% of mouse islet mass167. PP cells are found in the islet and sparingly throughout 1152 
the gastrointestinal tract, and release PP in response to meals168. PP regulates satiety and 1153 
decreases appetite and food intake in rodents and humans with no apparent paracrine effect on 1154 
insulin and glucagon levels169.  1155 
Epsilon cells  1156 
Epsilon cells are the fifth endocrine cell type and are defined by the expression of ghrelin, 1157 
classically known as the “hunger hormone”. The epsilon cells increase in number throughout 1158 
development reaching as high as 30% of the islet mass before decreasing to <5% in neonatal and 1159 
<1% in adult islets170. Whether they play a role in both developing and adult islets is currently 1160 
undefined.  1161 
Endothelial cells  1162 
Endothelial cells that make up the microvasculature of the islet are essential to proper endocrine 1163 
function as the islet cells require high blood flow and blood volume to effectively sense nutrients 1164 
and distribute their hormones. Beta cells (and to some extent alpha cells) produce a number of 1165 
angiogenic and angiostatic factors that target endothelial cell receptors including VEGF-A and 1166 
Angiopoietin 1171. Defects in beta cell-endothelial cell crosstalk in mice result in impaired GSIS 1167 
and angiogenesis is vital for successful integration of transplanted islets172.  1168 
Pericytes  1169 
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Pericytes associate closely with islet capillaries, and dynamically regulate blood flow by 1170 
constricting or dilating capillaries in response to signals from beta cells, endothelial cells and 1171 
peripheral nerves173. The pericytes exhibit a certain amount of plasticity as vascular damage to 1172 
islets during type 1 diabetes increases pericyte density as a possible healing response. 1173 
Conversely, in type 2 diabetes the opposite occurs and vascular coverage decreases174. This 1174 
likely contributes to impaired diabetic GSIS due to compromised in blood flow. Interestingly, 1175 
pericytes also regulate beta cell function independent from their role in controlling vasculature. 1176 
Beta cell insulin content and expression are reduced and GSIS is impaired when pericytes are 1177 
ablated suggesting that pericytes sustain beta cell maturity in a paracrine fashion175.  1178 
Glial/Schwann cells  1179 
Glial cells are peripheral neuronal cells that have been shown to both penetrate the core of islets 1180 
and form a peripheral sheath around the islet mantle. This sheath becomes more dense in 1181 
response to injury such as stress or autoimmune attack during type 1 diabetes, reflecting a 1182 
protective role of the glial cells173. The glial cells also serve a paracrine role: glial-derived 1183 
neurotrophic factor increases beta cell mass and insulin content, which improves glucose 1184 
tolerance176.  1185 
Resident macrophages  1186 
The islet also contains resident macrophages, which, under non-inflammatory conditions, 1187 
contribute to endocrine cell development in mice by supporting normal alpha and beta cell 1188 
expansion177,178. 1189 
Stellate cells  1190 
Fibroblasts and myofibroblasts are uncommon in healthy islets, but contribute to fibrosis seen in 1191 
pancreatic diseases like pancreatitis and pancreatic cancer. Stellate cells are quiescent 1192 
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myofibroblast-like cells that secrete fibrous extracellular matrix proteins upon activation. Stellate 1193 
cells are primarily responsible for fibrosis that is occasionally observed in type 2 diabetes, which 1194 
has been linked to reduced insulin expression and apoptosis among beta cells179.  1195 
Acinar cells  1196 
The exocrine pancreatic acinar tissue releases digestive enzymes and is affected not just by 1197 
nutrient status following food intake, but also by local signaling from the endocrine islet. Insulin 1198 
potentiates amylase release while somatostatin and pancreatic polypeptide both inhibit exocrine 1199 
secretion180.  1200 
Rodent
Notable Characteristics
   • 60-80% β cells
   • 15-20% α cells
   • <10% δ cells
   • <1% other cells
   • Peripheral layer of 
     α  & δ cells
   • β  cell core
   • δ  cells have long 
     projections
   • Ample autonomic 
     innervation
Human
Notable Characteristics
   • 50-75% β cells
   • 25-35% α cells
   • 10% δ cells
   • <1% other cells
   • Variable composition
     and architecture  by
     islet size
   • δ  cells have no 
     distinct morphology
   • Sparsely innervated
Blood
Vessels
Autonomic
Innervationα cell δ cellβ cell
ε  & PP
cells
Insulin
GLP-1
Ghrelin
Skeletal Muscle
 Glycogenolysis
 Gluconeogenesis
 Glucose uptake
 Glycogen synthesis
 Amino acid uptake
 Protein synthesis
GI Tract
Fight or
ight
Rest &
digest
ACh NE
CNS
ANS
Adipose Tissue
 Glucose uptake
 Glycogen synthesis
 Triglyceride synthesis
 Lipolysi s
 Lipolysi s
Glucose
Amino acids
Free fatty acids
Glucagon
Liver
 Glycogenolysis
 Glycogen synthesis
 Glycogenolysis
 Gluconeogenesis
 Amino acid uptake
 Fatty acid catabolism
Pancreas
GIP
bd
a
Ffar1
Gabbr2 Galr1
Ghsr
Sstr1
Ffar4 Crhr2
Chrm4
Glp1r
Adra2a
GcgrChrm3
P2ry6
Ffar3
Adora2b
Hcar2
Vipr1 Gipr
Taar1
Ffar2
P2ry12
Adora1
P2ry1
Cnr1
Oxtr
Avpr1b Sstr2
Gpr119
Hcar1
Adrb1
Gabbr1
Adora2a
Mc4r
Sstr3
Cprl1
Avpr1a
Gper1
Crhr1
Vipr2
Adra1a
Ptger3
Mas1
Ednra
Tacr3
Cxcr4
Gpr75
Galr2
Ptger1
Gpr27
Gpr39
Kiss1r
Ccr1
Gpr65
Gpr3
Adora3
Adrb2
Ptger4
Gpr84
b Islet GPCRs
Gas-coupled GPCRs
Gai-coupled GPCRs
Gaq-coupled GPCRs
miscellaneous GPCRs
d
a
b
Slc2a2
Slc2a1
Gabrb3
Glrb
Gabrg1
Slc2a3
Slc38a5
Gria2
Gria3
Slc2a10
Grik4
Grik2
Gabrg2
Gabrg3
Grid1
Gabre
Grik3
Slc2a12
Gabra5
Glra4
Slc15a3
Slc1a1
Slc38a1
Grin1
Slc7a11
Grin2c
Slc6a19
Slc6a9
Slc7a3
Slc1a4
Slc7a5Slc2a5
Slc2a13
Slc7a2
Slc7a8
Slc38a4
Grik5
Slc16a10
Slc3a2
Slc1a5 Slc7a7
Slc2a9
Slc2a8
Slc7a14Glra1
Slc38a2Slc38a10
Slc7a1
Slc38a7Slc30a8
Slc7a1
Slc6a17
c Islet transporters
Neutral and cationic amino acid transporter (Slc6a family)
Sodium-coupled neutral amino acid transporter (Slc38a family)
Glutamate and neutral amino acid transporters (Slc1a family)
Glucose transporters (Slc2a family)
Cationic amino acid transporters (Scl7a1-4)
Heteromeric amino acid transporters (Slc3a/7a5-14)
Glutamate receptors
Ionotropic GABA receptors
Glycine receptors
Zn2+ transporters (Slc30a family)
miscellaneous transporters
d
a
xaya
xa
xd
yd
yb
yd
Glp1r
ya
Glp1r
b  cells
Glp1r
a  cells
Glp1r
d  cells
ln(rp
km[a
]) ln(rpkm[
d])
ln
(rp
km
[b]
)
b
a Example
Insulin Glucagon Glucagon
Healthy
Islet
Alpha cell
inhibitors
Somatostatin
SSTR2
Delta cell
inhibitors
Acetylcholine
CHRM4
Diabetic
Islet
Beta cell
activators
Glucagon
GLP1R / GCGR
   ACh CRH
CHRM3 CRHR1
Alpha cell
inhibitors
Insulin
INSR
  5-HT GABA
HTR1F GABAAR
Delta cell
activators
Urocortin3
CRHR2
Beta cell
inhibitors
Somatostatin
SSTRs
SomatostatinSomatostatin
glucose setpoint
0 3 6 9 12 15
hypo hyper
somatostatin
glu
cag
on
ho
rm
on
e 
se
cr
et
io
n
insulin
glucose (mM)
glucose setpoint
glucose (mM)
0 3 6 9 12 15
hypo hyper
som
ato
stat
inglucagon
ho
rm
on
e 
se
cr
et
io
n
insuli
nhealthy
islet
a b
c d
• Loss of beta cell-
   derived signals
• Aberrant glucagon 
   secretion
• Aberrant SST
   secretion?
diabetes
